Zepbound is Eli Lilly’s FDA-approved tirzepatide for chronic weight management, approved November 2023 at doses up to 15 mg weekly.

Mounjaro is Eli Lilly’s brand-name tirzepatide, FDA-approved in May 2022 for type 2 diabetes.

Switching between Mounjaro, Zepbound, and compounded tirzepatide is straightforward because the active ingredient is identical.

Compounded tirzepatide is a sterile injectable peptide that needs refrigeration at 36°F to 46°F (2°C to 8°C).

Compounded tirzepatide vials should be refrigerated between 36-46°F (2-8°C) until first use.

Most tirzepatide side effects are gastrointestinal and concentrated in the first 12-16 weeks. In SURMOUNT-1 (Jastreboff et al.

Average weight loss on tirzepatide from SURMOUNT-1 (Jastreboff et al.

Introduction Compounded tirzepatide is the same dual GIP/GLP-1 agonist molecule as Mounjaro® and Zepbound®, made by licensed 503A or 503B pharmacies and dispensed through…

Tirzepatide is a dual incretin agonist. It binds and activates both the GIP receptor and the GLP-1 receptor with engineered selectivity.